Methazolamide

Methazolamide
Ball-and-stick model of the methazolamide molecule
Clinical data
Other namesN-(3-Methyl-5-sulfamoyl-3H-1,3,4-thiadiazol-2-ylidene) ethanamide
AHFS/Drugs.comMonograph
MedlinePlusa601233
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding~55%
Elimination half-life~14 hours
Identifiers
  • N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.008.243 Edit this at Wikidata
Chemical and physical data
FormulaC5H8N4O3S2
Molar mass236.26 g·mol−1
3D model (JSmol)
  • O=S(=O)(C\1=N\N(C(=N/C(=O)C)/S/1)C)N
  • InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4- checkY
  • Key:FLOSMHQXBMRNHR-DAXSKMNVSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Methazolamide (trade name Neptazane) is a potent carbonic anhydrase inhibitor. It is indicated in the treatment of increased intraocular pressure (IOP) in chronic open-angle glaucoma and secondary glaucoma. Also it is used preoperatively in acute angle-closure (narrow-angle) glaucoma where lowering the IOP is desired before surgery.

This drug has displayed teratogenic effects in rats. Compared to another drug in the same class, acetazolamide, methazolamide requires a lower dose when administered to patients.